You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 20, 2024

Details for Patent: 7,635,773


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,635,773
Title:Sulfoalkyl ether cyclodextrin compositions
Abstract:SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD composition comprises a sulfoalkyl ether cyclodextrin and less than 100 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Inventor(s): Antle; Vincent (Olathe, KS)
Assignee: CyDex Pharmaceuticals, Inc. (Lenexa, KS)
Application Number:12/404,174
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,635,773
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Process; Compound; Device;

Drugs Protected by US Patent 7,635,773

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Baxter Hlthcare NEXTERONE amiodarone hydrochloride INJECTABLE;INJECTION 022325-001 Dec 24, 2008 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Baxter Hlthcare NEXTERONE amiodarone hydrochloride INJECTABLE;INJECTION 022325-002 Nov 16, 2010 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Baxter Hlthcare NEXTERONE amiodarone hydrochloride INJECTABLE;INJECTION 022325-003 Nov 16, 2010 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Lundbeck Pharms Llc CARNEXIV carbamazepine SOLUTION;INTRAVENOUS 206030-001 Oct 7, 2016 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-001 Nov 5, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-002 Nov 5, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,635,773

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009241858 ⤷  Sign Up
Brazil PI0905080 ⤷  Sign Up
Canada 2702603 ⤷  Sign Up
Canada 2771879 ⤷  Sign Up
China 101959508 ⤷  Sign Up
China 105288650 ⤷  Sign Up
China 114053423 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.